Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Raw Materials (2020 - 2026)

Maxcyte has reported Raw Materials over the past 6 years, most recently at $3.9 million for Q4 2025.

  • Quarterly Raw Materials fell 18.08% to $3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2025, down 18.08% year-over-year, with the annual reading at $3.9 million for FY2025, 18.08% down from the prior year.
  • Raw Materials was $3.9 million for Q4 2025 at Maxcyte, roughly flat from $3.9 million in the prior quarter.
  • Over five years, Raw Materials peaked at $6.0 million in Q1 2023 and troughed at $1.6 million in Q3 2021.
  • The 5-year median for Raw Materials is $4.7 million (2024), against an average of $4.5 million.
  • Year-over-year, Raw Materials surged 224.18% in 2022 and then crashed 30.53% in 2025.
  • A 5-year view of Raw Materials shows it stood at $2.7 million in 2021, then surged by 110.54% to $5.7 million in 2022, then grew by 0.76% to $5.7 million in 2023, then dropped by 17.16% to $4.7 million in 2024, then decreased by 18.08% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Raw Materials are $3.9 million (Q4 2025), $3.9 million (Q3 2025), and $4.1 million (Q2 2025).